Skip to main navigation

Investor Relations

Overview
News & Events
- News Releases
- Events & Presentations
Stock Information
Corporate Governance
Financial Information
Shareholder Services
Videos

Quarterly Results

Quarterly Results

Show all

2020

Q3

Advaxis Reports Third Quarter Ended July 31, 2020 Financial Results and Provides a Business Update
Form 10-Q

Q2

Form 10-Q
Advaxis Reports Second Quarter Ended April 30, 2020 Financial Results and Provides a Business Update

Q1

Form 10-Q
Advaxis Reports First Quarter Ended January 31, 2020 Financial Results and Provides a Pipeline Update

2019

Q4

Form 10-K
Advaxis Reports Fiscal Year 2019 Financial Results and Provides a Business Update

Q3

Form 10-Q
Advaxis Reports Fiscal Third Quarter 2019 Financial Results and Provides Pipeline Update

Q2

Form 10-Q
Advaxis Reports Second Quarter Fiscal 2019 Financial Results and Provides Pipeline Update

Q1

Form 10-Q
Advaxis Reports First Quarter Fiscal 2019 Financial Results and Provides Clinical Pipeline Update

2018

Q4

Form 10-K
Advaxis Reports Fiscal Year 2018 Financial Results and Provides a Business Update

Q3

Form 10-Q
Advaxis Reports Fiscal 2018 Third Quarter Business Highlights and Financial Results

Q2

Form 10-Q
Advaxis Announces Prioritization of Product Portfolio and Reports Fiscal 2018 Second Quarter Financial Results

Q1

Form 10-Q
Advaxis Reports Fiscal 2018 First Quarter Financial Results and Announces Clinical Hold in Axalimogene Filolisbac Phase 1/2 Combination Study with AstraZeneca’s IMFINZI® (Durvalumab)

Investor Tools

Print Page
Email Alerts
RSS Feeds
Contact IR

Request Email Alerts

© 2020 Advaxis, Inc.. All rights reserved.

Facebook
Twitter
LinkedIn
Google+